Kim, Daniel W.
Lee, Grace
Hong, Theodore S.
Li, Guichao
Horick, Nora K.
Roeland, Eric
Keane, Florence K.
Eyler, Christine
Drapek, Lorraine C.
Ryan, David P.
Allen, Jill N.
Berger, David
Parikh, Aparna R.
Mullen, John T.
Klempner, Sam
Clark, Jeffrey W.
Wo, Jennifer Y.
Article History
Received: 3 August 2021
Accepted: 16 August 2021
First Online: 6 September 2021
Disclosures
: T.S.H. has served as a compensated consultant for Merck, Novocure, and Synthetic Biologics and serves as research support for Ipsen, BMS, Astra-Zeneca, Taiho, IntraOp, and Tesaro (GlaxoSmithKline). S.J.K. has served as a compensated consultant for Merck, BMS, Eli Lilly, Natera, Astellas, Daiichi Sankyo, and Pieris Oncology and owns stock/equity in Turning Point Therapeutics, Inc. A.R.P. has received personal fees from Checkmate Pharma, Eli Lilly, Pfizer, Roche, C2I genomics, Research to Institution Puretech, PMV Pharma, Plexxicon, Takeda, BMS, and Novartis. D.P.R. owns equity in Exact Sciences and Acworth Pharmaceuticals, has a grant in SU2C, and serves as a publisher for Uptodate.